

PROSONIX AND SYRRIS ANNOUNCE MARKETING PARTNERSHIP FOR PROSONIX SONOLAB™ LABORATORY SCALE EQUIPMENT

Prosonix Ltd (Oxford, UK) and Syrris (Royston, UK) are delighted to announce a new marketing partnership which positions Syrris as the prime channel to market for Prosonix's new SonoLab™ laboratory scale sonocrystallization and sonoprocessing equipment.

Prosonix are acknowledged leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries. In particular, Prosonix proprietary sonocrystallization technology delivers usable and practical Complete Crystallization Control™ across a wide range of crystallization processes by controlling nucleation without the need for external seeds or operating at troublesome high supersaturation. Prosonix's sonocrystallization technology is increasingly being recognised as the *defacto* first choice for pharmaceutical API crystallization and isolation.

Uniquely, SonoLab™ incorporates the same bonded transducer based design that are featured in the operation of Prosonix larger scale Prosonitron™ reactors, which are already proven in commercial operation and can operate in GMP and ATEX environments in primary and secondary API production.

The Syrris Atlas™ platform is rapidly becoming acknowledged as the new default standard and market leading automated laboratory reactor suite. The Atlas™ package of an ergonomic design, modularity, innate simplicity, reliability, intelligent intuitive software are a highly desirable and cost effective solution compared to other systems.

Utilising the new SonoLab™ equipment in conjunction with the Atlas™ platform now provides customers a sound basis for quality ultrasonic experimentation and a seamless transition from laboratory to pilot plant, at scales ranging from 100 ml up to 100L, safe in the knowledge that laboratory results can be successfully implemented at manufacturing scale using the Prosonitron™ system.

Commenting on the deal, Prosonix CEO David Hipkiss said,

"I am delighted to be able to announce this partnership with Syrris, the rapidly emerging leader in automated laboratory reactors. It provides Prosonix' global pharmaceutical customers a highly focussed and cost effective means of accessing our process technology at small scale. We look forward to working with Syrris in the months and years ahead."

Adding his approval, Mark Gilligan, Syrris CEO said,

"Prosonix' suite of particle engineering technologies represent a potential ideal solution to a range of manufacturing and formulation problems that are directly related to the historic methods of crystallizing active pharmaceutical ingredients, currently commonly employed throughout the pharmaceutical industry. This new partnership is an ideal and further differentiation for Syrris global product offering in automated reactor platforms."

For more Information contact:

Prosonix

David Hipkiss
CEO
Prosonix Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA, UK

Tel + 44 (0) 1865 784 250
Web www.prosonix.co.uk

Syrris

Mark Gilligan
CEO
Syrris Limited
27 Jarman Way
Royston,
Hertfordshire,
SG8 5HW, UK

Tel + 44 (0) 1763 242 555
Web www.syrris.com

Notes for Editors September 2008

About Prosonix Ltd

www.prosonix.co.uk

Based in Oxford UK and Experts in Sound Science™, Prosonix are acknowledged leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries.

Prosonix's team of chemists and engineers combine to give Prosonix a unique multidisciplinary approach and competitive advantage to solve customers complex particle engineering process problems, leveraging it's proprietary intellectual property and patented ultrasonic processing equipment to deliver long term and sustainable value added solutions, enabling the cost effective manufacture of better medicines.

Prosonix's core markets are in the Pharmaceutical and Chemical industries, having secured over 50 worldwide customers to date.

Prosonitron™, Prosonix's world leading patented sonocrystallization process and reactor technology is already proven across scale, facilitating the Complete Crystallization Control™ of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance. New and proprietary process variants include DISCUS™ and UMAX™ for the advanced particle engineering of microcrystalline active ingredients. In addition a new range of small scale SonoLab™ equipment is now available for laboratory and kilo lab use. Prosonitron™ technology is increasingly being recognised as the *defacto* first choice in pharmaceutical API crystallization and isolation.

SAX™, an award winning sonocrystallization development, is a novel ultrasonic particle engineering and drug delivery technology with world beating potential, and builds on Prosonix core Prosonitron™ technology. SAX™ can produce highly engineered single and combination microcrystalline drug particles that are ideally suited for inhalation, without the need for destructive milling or micronisation processes. SAX™ particles have better stability, formulation consistency, eliminates dose-to-dose variation and exhibit potentially improved efficacy per unit dose than those made by other techniques. Prosonix in-licensed the SAX™ technology from the University of Bath on a world wide exclusive basis in February 2007.

In January 2008 Prosonix in-licensed a novel particle rounding technology process patent from Rafael Industries(Haifa, Israel) Importantly the process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging. Used in combination, the Rafael process technology and the proven Prosonix Prosonitron™ process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems.

Underpinning Prosonix's leadership in commercializable crystallization technology is CrystalGEM™, an award winning predictive crystallization service that significantly enhances crystallization screening productivity in pharmaceutical development and SonoLab™, a suite of designed for purpose small scale reactors that can be used by the laboratory chemist with confidence, knowing that a proven scale up method already exists.

Complementing its market led internal R&D programs, Prosonix is also actively engaged with several strategic partnerships with leading academic and technology institutions, including the University of Bath, University of Coventry, and the University of Leeds.

Prosonix is further supported by leading industrial and academic consultants including but not limited to Dr Rob Price (University of Bath, UK), Dr Kevin Roberts (University of Leeds, UK) and Professor Tim Mason (University of Coventry).

About Syrris Ltd

www.syrris.com

Established in 2001, Syrris Limited is one of the fastest growing science SMEs in the UK employing over 30 scientists and engineers at its facility in Royston (near Cambridge). Founders Mark Gilligan and Richard Gray come from a background of developing automation products for chemists at companies such as The Technology Partnership (TTP) and Mettler Toledo.

Syrris develops general productivity tools for chemists such as the Atlas™ automated chemistry systems. Atlas™ can be configured into a wide range of different systems including Lithium and Sodium for round bottom flasks (magnetically and overhead stirred respectively) and Potassium for jacketed vessels. Other Atlas systems, designed for specific applications, including calorimetry, volumetric dosing, gravimetric dosing, pH, etc, are also available.

Syrris also specialise in flow reactors for R&D chemists, including FRX: a low cost flow chemistry system and Africa (Automated Flow Reaction Incubation and Control Apparatus): a modular system for library synthesis, aqueous work-up and reaction optimization that will ultimately reduce the time taken to develop, synthesize, screen and review a chemical entity, thus vastly speeding up the drug discovery process.

In recognition of its technological achievements, Syrris has been awarded a prestigious UK DTI SMART Exceptional Grant. Syrris has also won a significant DTi MNT (Micro and Nano Technology) award which is being used to establish a new subsidiary called The Dolomite Centre Ltd. This new company is focused on design and fabrication of Microfluidic devices for a wide range of applications.

----- ENDS -----